Incyte (INCY) Projected to Announce Earnings on Tuesday

Incyte (NASDAQ:INCY) is expected to release its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Incyte to announce earnings of $2.10 per share and revenue of $1.4588 billion for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.38 by $0.43. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same period last year, the company posted $1.16 earnings per share. Incyte’s revenue was up 20.9% compared to the same quarter last year. On average, analysts expect Incyte to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Incyte Price Performance

INCY opened at $115.65 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.68 and a quick ratio of 3.60. The firm has a market capitalization of $23.10 billion, a PE ratio of 16.33, a price-to-earnings-growth ratio of 1.06 and a beta of 0.76. Incyte has a 1 year low of $67.17 and a 1 year high of $119.60. The business’s 50-day moving average is $105.29 and its two-hundred day moving average is $101.16.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. BMO Capital Markets raised their price target on shares of Incyte from $94.00 to $112.00 and gave the stock a “market perform” rating in a report on Monday, July 13th. Royal Bank Of Canada lifted their price objective on shares of Incyte from $95.00 to $99.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Incyte in a research note on Monday, June 29th. Truist Financial lifted their price target on Incyte from $103.00 to $105.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Finally, Sanford C. Bernstein assumed coverage on Incyte in a report on Thursday, May 21st. They issued a “market perform” rating and a $99.00 price target for the company. Eight research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $109.95.

Institutional Investors Weigh In On Incyte

A number of large investors have recently modified their holdings of INCY. MUFG Securities EMEA plc purchased a new stake in shares of Incyte during the 2nd quarter worth $32,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Incyte during the 2nd quarter worth about $33,000. Atlas Capital Advisors Inc. purchased a new stake in Incyte during the fourth quarter worth approximately $35,000. Geneos Wealth Management Inc. increased its stake in Incyte by 350.0% in the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 588 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in Incyte by 153.8% during the third quarter. CIBC Private Wealth Group LLC now owns 726 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 440 shares in the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.